Physical dependence

Symptoms

Physical dependence can manifest itself in the appearance of both physical and psychological symptoms which are caused by physiological adaptions in the central nervous system and the brain due to chronic exposure to a substance. Symptoms which may be experienced during withdrawal or reduction in dosage include increased heart rate and/or blood pressure, sweating, and tremors. More serious withdrawal symptoms such as confusion, seizures, and visual hallucinations indicate a serious emergency and the need for immediate medical care. Sedative hypnotic drugs such as alcohol, benzodiazepines, and barbiturates are the only commonly available substances that can be fatal in withdrawal due to their propensity to induce withdrawal convulsions. Abrupt withdrawal from other drugs, such as opioids can cause an extremely painful withdrawal that is very rarely fatal in patients of general good health and with medical treatment, but is more often fatal in patients with weakened cardiovascular systems; toxicity is generally caused by the often-extreme increases in heart rate and blood pressure (which can be treated with clonidine), or due to arrhythmia due to electrolyte imbalance caused by the inability to eat, and constant diarrhea and vomiting (which can be treated with loperamide and ondansetron respectively) associated with acute opioid withdrawal, especially in longer-acting substances where the diarrhea and emesis can continue unabated for weeks, although life-threatening complications are extremely rare, and nearly non-existent with proper medical management.

Treatment

Treatment for physical dependence depends upon the drug being withdrawn and often includes administration of another drug, especially for substances that can be dangerous when abruptly discontinued or when previous attempts have failed. Physical dependence is usually managed by a slow dose reduction over a period of weeks, months or sometimes longer depending on the drug, dose and the individual. A physical dependence on alcohol is often managed with a cross tolerant drug, such as long acting benzodiazepines to manage the alcohol withdrawal symptoms.

Drugs that cause physical dependence

• All μ-opioids with any (even slight) agonist effect, such as (partial list) morphine, heroin, codeine, oxycodone, buprenorphine, nalbuphine, methadone, and fentanyl, but not agonists specific to non-μ opioid receptors, such as salvinorin A (a k-opioid agonist), nor opioid antagonists or inverse agonists, such as naltrexone (a universal opioid inverse agonist)
• All GABA agonists and positive allosteric modulators of both the GABA-A ionotropic receptor and GABA-B metabotropic receptor subunits, including (partial list):
  • alcohol (alcoholic beverage) (cf. alcohol dependence, alcohol withdrawal, delirium tremens)
  • barbiturates such as phenobarbital, sodium thiopental and secobarbital
  • benzodiazepines such as diazepam (Valium), lorazepam (Ativan), and alprazolam (Xanax) (see benzodiazepine dependence and benzodiazepine withdrawal syndrome)
  • nonbenzodiazepine hypnotics (z-drugs) such as zopiclone and zolpidem.
  • gamma-hydroxybutyric acid (GHB) and 1,4-butanediol
  • carisoprodol (Soma) and related carbamates (tybamate, meprobamate, ethinamate etc.)
  • baclofen (Lioresal) and its non-chlorinated analogue phenibut
  • chloral hydrate
  • glutethimide
  • clomethiazole
  • methaqualone (Quaalude)
• nicotine (tobacco) (cf. nicotine withdrawal)
• gabapentinoids such as gabapentin (Neurontin), pregabalin (Lyrica), and phenibut (Noofen), which are inhibitors of α2δ subunit-containing
• antiepileptic drugs such as valproate, lamotrigine, tiagabine, vigabatrin, carbamazepine and oxcarbazepine, and topiramate
• antipsychotic drugs such as clozapine, risperidone, olanzapine, haloperidol, thioridazine, etc.
• commonly prescribed antidepressants such as the selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) (cf. SSRI/SNRI withdrawal syndrome)
• blood pressure medications, including beta blockers such as propranolol and alpha-adrenergic agonists such as clonidine
• androgenic-anabolic steroids
• glucocorticoids
• topical decongestants such as xylometazoline and oxymetazoline

Rebound syndrome

Main article: Rebound effect

A wide range of drugs whilst not causing a true physical dependence can still cause withdrawal symptoms or rebound effects during dosage reduction or especially abrupt or rapid withdrawal. These can include caffeine, stimulants, steroidal drugs and antiparkinsonian drugs. It is debated whether the entire antipsychotic drug class causes true physical dependency, a subset, or if none do. But, if discontinued too rapidly, it could cause an acute withdrawal syndrome. When talking about illicit drugs rebound withdrawal, especially with stimulants, it is sometimes referred to as "coming down" or "crashing".

Some drugs, like anticonvulsants and antidepressants, describe the drug category and not the mechanism. The individual agents and drug classes in the anticonvulsant drug category act at many different receptors and it is not possible to generalize their potential for physical dependence or incidence or severity of rebound syndrome as a group so they must be looked at individually. Anticonvulsants as a group however are known to cause tolerance to the anti-seizure effect. SSRI drugs, which have an important use as antidepressants, engender a discontinuation syndrome that manifests with physical side effects; e.g., there have been case reports of a discontinuation syndrome with venlafaxine (Effexor).

References

References

1. (2011-02-02). "Definition of physical dependence - NCI Dictionary of Cancer Terms".
2. "All about Addiction". Medical News Today.
3. (1992). "Benzodiazepine dependence and withdrawal: identification and medical management". J Am Board Fam Pract.
4. "Withdrawal From Antidepressants: Symptoms, Causes, Treatments".
5. "Drug addiction (substance use disorder)". Mayo Clinic.
6. (January 2013). "Pharmacological Intervention of Nicotine Dependence". BioMed Research International.
7. (May 2002). "The role of spinal neuropeptides and prostaglandins in opioid physical dependence". Br. J. Pharmacol..
8. (July 2008). "Mapping a locus for alcohol physical dependence and associated withdrawal to a 1.1 Mb interval of mouse chromosome 1 syntenic with human chromosome 1q23.2-23.3". [[Genes, Brain and Behavior]].
9. Sikdar S. (July 1998). "Physical dependence on zopiclone. Prescribing this drug to addicts may give rise to iatrogenic drug misuse". BMJ.
10. (January 1997). "Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence". Addiction.
11. (January 2017). "Oral Baclofen Withdrawal Resulting in Progressive Weakness and Sedation Requiring Intensive Care Admission". The Neurohospitalist.
12. (September 2015). "[Nicotine dependence]". Nihon Rinsho. Japanese Journal of Clinical Medicine.
13. (November 2012). "Are Tobacco Dependence and Withdrawal Related Amongst Heavy Smokers? Relevance to Conceptualizations of Dependence". Journal of Abnormal Psychology.
14. (June 2005). "Gabapentin withdrawal syndrome in the presence of a taper". Bipolar Disord.
15. (2019). "Acute phenibut withdrawal: A comprehensive literature review and illustrative case report". Department of Anesthesiology and Perioperative Medicine, Mayo Clinic.
16. (November 2001). "Sudden withdrawal of carbamazepine increases cardiac sympathetic activity in sleep". Neurology.
17. (December 1999). "Effects of the calcium antagonists verapamil and nitrendipine on carbamazepine withdrawal". Methods Find Exp Clin Pharmacol.
18. Meyer, Jonathan M.. (January 2011). "Goodman and Gilman's The Pharmacological Basis of Therapeutics, Twelfth Edition". McGraw-Hill Education / Medical.
19. (2008). "[Hypomania/mania induced by cessation of antidepressant drugs]". Turk Psikiyatri Derg.
20. (May 2008). "The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study". J. Psychopharmacol. (Oxford).
21. (September 2008). "Venlafaxine dependence in a patient with a history of alcohol and amineptine misuse". Addiction.
22. "MedlinePlus Medical Encyclopedia: Drug abuse and dependence".
23. (May 2005). "Withdrawal syndrome following cessation of antihypertensive drug therapy". Int. J. Clin. Pract..
24. (2005). "Behavioural manifestations of anabolic steroid use". CNS Drugs.
25. (2004). "Effects of androgenic-anabolic steroids in athletes". Sports Med.
26. [http://www.cqld.ca/livre/en/en/20-doping.htm] {{webarchive. link. (May 19, 2013)
27. Lakatos, Lili. (2025-03-28). "Does nose spray addiction exist? A qualitative analysis of addiction components in rhinitis medicamentosa". Journal of Behavioral Addictions.
28. (July 1988). "Exacerbation of psychosis after discontinuation of carbamazepine treatment". Am J Psychiatry.
29. (May 2019). "Antidepressant Withdrawal and Rebound Phenomena". Deutsches Ärzteblatt Online.
30. (December 1990). "Low-dose caffeine physical dependence in humans". J. Pharmacol. Exp. Ther..
31. (December 1984). "CNS stimulants and the look-alike drugs". Psychiatr. Clin. North Am..
32. (2002). "Can stimulant rebound mimic pediatric bipolar disorder?". J Child Adolesc Psychopharmacol.
33. Danke F. (1975). "[Methylphenidate addiction--Reversal of effect on withdrawal]". Psychiatr Clin (Basel).
34. (2002). "A boy who stops taking stimulants for "ADHD": commentaries on a Pediatrics case study". Ethical Hum Sci Serv.
35. (1993). "[Risk related to withdrawal from non-psychotropic drugs]". Thérapie.
36. (2008). "Current medical diagnosis & treatment, 2008". McGraw-Hill Medical.
37. BNF. (2008). "Antipsychotic drugs". British National Formulary.
38. (August 2006). "Experimental and Clinical Evidence for Loss of Effect (Tolerance) during Prolonged Treatment with Antiepileptic Drugs". Epilepsia.